Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), announced multiple resmetirom data presentations at the upcoming American Association… read more.
Obesity can give rise to a variety of health concerns. Nonalcoholic steatohepatitis (NASH)—a type of fatty liver disease that might progress to cancer—is particularly prevalent among obese people…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
